|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-4-1
|
|
pubmed:abstractText |
A structure-activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the treatment of hormone refractory prostate cancer.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1520-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
8
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2779-96
|
|
pubmed:dateRevised |
2011-9-30
|
|
pubmed:meshHeading |
pubmed-meshheading:20218717-Androgen Receptor Antagonists,
pubmed-meshheading:20218717-Androgens,
pubmed-meshheading:20218717-Animals,
pubmed-meshheading:20218717-Cell Line, Tumor,
pubmed-meshheading:20218717-Dose-Response Relationship, Drug,
pubmed-meshheading:20218717-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:20218717-Male,
pubmed-meshheading:20218717-Orchiectomy,
pubmed-meshheading:20218717-Prostatic Neoplasms,
pubmed-meshheading:20218717-Receptors, Androgen,
pubmed-meshheading:20218717-Structure-Activity Relationship,
pubmed-meshheading:20218717-Thiohydantoins,
pubmed-meshheading:20218717-Tumor Burden,
pubmed-meshheading:20218717-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
|
|
pubmed:affiliation |
Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, USA. jung@chem.ucla.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
